Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 8.9% - Should You Sell?

Key Points

• Armata Pharmaceuticals shares fell 8.9% to $3.07 in Monday trading, with volume below the stock’s average. The stock is also trading well below its 50-day and 200-day moving averages of $4.43 and $6.60.
• Analysts remain generally positive, with two Buy ratings and one Hold rating producing a “Moderate Buy” consensus and a $15.00 average price target—substantially above the current share price.
• The clinical-stage biotechnology company reported a quarterly loss of $0.27 per share but beat expectations, while revenue of $2.51 million exceeded estimates of $0.40 million. Institutional investors own only 3.57% of outstanding shares, despite recent buying by firms including BlackRock.

Shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) traded down 8.9% during mid-day trading on Monday. The company traded as low as $3.07 and last traded at $3.07. Approximately 88,257 shares traded hands during trading, a decline of 25% from the average daily volume of 118,054 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Armata Pharmaceuticals in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Performance

The stock has a market capitalization of $114.14 million, a P/E ratio of -0.40 and a beta of 1.40. The firm has a 50-day moving average price of $4.43 and a 200 day moving average price of $6.60.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The business had revenue of $2.51 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post 0.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company's stock worth $120,000 after buying an additional 8,198 shares during the last quarter. Deutsche Bank AG bought a new position in shares of Armata Pharmaceuticals in the second quarter worth $78,000. Bank of New York Mellon Corp bought a new stake in Armata Pharmaceuticals during the second quarter valued at approximately $193,000. Sei Investments Co. bought a new stake in Armata Pharmaceuticals in the 1st quarter worth approximately $760,000. Finally, BlackRock Inc. bought a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $3,629,000. Institutional investors and hedge funds own 3.57% of the company's stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company's pipeline includes investigational phage therapies for serious respiratory and systemic infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.